NVE (NVEC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 Jun, 2026Executive summary
Net income rose 27% in the most recent quarter, with core non-defense sales up 34%.
Completed a two-year, multimillion-dollar expansion, boosting production capacity and manufacturing precision.
Focused on four growth markets: medical devices, robotics, IoT/AIoT, and power conversion.
Continued investment in R&D, launching new sensors and advancing next-generation technologies.
Expanded sales efforts with new demonstrations, increased tradeshow presence, and a new distributor.
Voting matters and shareholder proposals
Shareholders will vote on the appointment of Pete Eames as president and CEO at the upcoming Annual Meeting.
Nomination of Carolyn Valentine as a new director to expand and strengthen the Board.
Board of directors and corporate governance
Daniel A. Baker will step down as president and CEO, remaining as Board chairman.
Terry Glarner will retire as chairman but continue as a Board member.
Board expansion aims to enhance governance as the company grows.
Latest events from NVE
- Director elections, executive pay, and auditor ratification headline the 2026 annual meeting.NVEC
Proxy filing22 Jun 2026 - Shareholders will vote on directors, executive pay, and auditor ratification at the 2026 meeting.NVEC
Proxy filing22 Jun 2026 - Board expansion, executive pay, and auditor ratification headline the August 2026 proxy.NVEC
Proxy filing22 Jun 2026 - Quarterly net income rose 27% year-over-year, driven by strong product sales and margin gains.NVEC
Q4 20267 May 2026 - Quarterly revenue up 23% and net income up 11%, with a $1.00 dividend announced.NVEC
Q3 202614 Apr 2026 - Revenue and net income declined, but gross margin and cash returns to shareholders remained strong.NVEC
Q1 20253 Feb 2026 - Gross margin rose to 86% as R&D revenue surged and a $1.00 dividend was declared.NVEC
Q2 202519 Jan 2026 - Revenue and net income fell, but gross margin improved to 84% and a dividend was declared.NVEC
Q3 20259 Jan 2026 - Maintained strong earnings, expanded R&D, and appointed a new director with medical expertise.NVEC
Proxy Filing1 Dec 2025